Advicenne SA Reports Growth and Optimistic Outlook

Advicenne SA (FR:ALDVI) has released an update.

Advicenne SA reported a 28% increase in Sibnayal gross sales reaching €1.25 million for the first half of 2024, alongside progress towards operating breakeven, and a stable cash position of €2.0 million with visibility into the first quarter of 2025. The company is also optimistic about its regulatory and commercial prospects in the U.S. for its ADV7103 treatment. Overall, Advicenne saw a 10% rise in gross sales to €2.46 million, and an improved operating loss of €2.84 million compared to the previous year.

For further insights into FR:ALDVI stock, check out TipRanks’ Stock Analysis page.